{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T02:02:53Z","timestamp":1774922573590,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["R01DA058018"],"award-info":[{"award-number":["R01DA058018"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA48353"],"award-info":[{"award-number":["DA48353"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s43440-026-00834-w","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T03:44:10Z","timestamp":1770608650000},"page":"431-445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Sigma1 receptor antagonist CM304 potentiates the antinociceptive effects of the cannabinoid receptor agonist delta9-tetrahydrocannabinol in rats and mice"],"prefix":"10.1007","volume":"78","author":[{"given":"Elmira","family":"Zolali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mallory","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiano","family":"Intagliata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas P.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis F.","family":"Restrepo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea R.","family":"Gamez-Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel A.","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa L.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lance R.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takato","family":"Hiranita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Obeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"McCurdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"834_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pharmthera.2009.07.001","volume":"124","author":"T Maurice","year":"2009","unstructured":"Maurice T, Su T-P. The Pharmacology of sigma-1 receptors. Pharmacol Ther. 2009;124:195\u2013206.","journal-title":"Pharmacol Ther"},{"key":"834_CR2","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2007.08.036","volume":"131","author":"T Hayashi","year":"2007","unstructured":"Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell. 2007;131:596\u2013610.","journal-title":"Cell"},{"key":"834_CR3","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1523\/JNEUROSCI.06-06-01757.1986","volume":"6","author":"AL Gundlach","year":"1986","unstructured":"Gundlach AL, Largent BL, Snyder SH. Autoradiographic localization of Sigma receptor binding sites in Guinea pig and rat central nervous system with (+) 3H-3-(3-hydroxyphenyl)-N-(1-propyl) piperidine. J Neurosci. 1986;6:1757\u201370.","journal-title":"J Neurosci"},{"key":"834_CR4","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.tins.2012.09.007","volume":"35","author":"S Kourrich","year":"2012","unstructured":"Kourrich S, Su T-P, Fujimoto M, Bonci A. The sigma-1 receptor: roles in neuronal plasticity and disease. Trends Neurosci. 2012;35:762\u201371.","journal-title":"Trends Neurosci"},{"key":"834_CR5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.pbb.2006.07.009","volume":"84","author":"T Maurice","year":"2006","unstructured":"Maurice T, Gr\u00e9goire C, Espallergues J. Neuro (active) steroids actions at the neuromodulatory sigma1 (\u03c31) receptor: biochemical and physiological evidences, consequences in neuroprotection. Pharmacol Biochem Behav. 2006;84:581\u201397.","journal-title":"Pharmacol Biochem Behav"},{"key":"834_CR6","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.lfs.2005.05.009","volume":"77","author":"T Hayashi","year":"2005","unstructured":"Hayashi T, Su T-P. The potential role of sigma-1 receptors in lipid transport and lipid raft reconstitution in the brain: implication for drug abuse. Life Sci. 2005;77:1612\u201324.","journal-title":"Life Sci"},{"key":"834_CR7","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.15252\/emmm.201606403","volume":"8","author":"S Watanabe","year":"2016","unstructured":"Watanabe S, Ilieva H, Tamada H, Nomura H, Komine O, Endo F, et al. Mitochondria-associated membrane collapse is a common pathomechanism in SIGMAR 1\u2010and SOD 1\u2010linked ALS. EMBO Mol Med. 2016;8:1421\u201337.","journal-title":"EMBO Mol Med"},{"key":"834_CR8","doi-asserted-by":"publisher","first-page":"e76941","DOI":"10.1371\/journal.pone.0076941","volume":"8","author":"T Mori","year":"2013","unstructured":"Mori T, Hayashi T, Hayashi E, Su T-P. Sigma-1 receptor chaperone at the ER-mitochondrion interface mediates the mitochondrion-ER-nucleus signaling for cellular survival. PLoS ONE. 2013;8:e76941.","journal-title":"PLoS ONE"},{"key":"834_CR9","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3389\/fnins.2019.00862","volume":"13","author":"DA Ryskamp","year":"2019","unstructured":"Ryskamp DA, Korban S, Zhemkov V, Kraskovskaya N, Bezprozvanny I. Neuronal sigma-1 receptors: signaling functions and protective roles in neurodegenerative diseases. Front Neurosci. 2019;13:862.","journal-title":"Front Neurosci"},{"key":"834_CR10","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1111\/j.1476-5381.2012.01942.x","volume":"166","author":"L Romero","year":"2012","unstructured":"Romero L, Zamanillo D, Nadal X, S\u00e1nchez-Arroyos R, Rivera\u2010Arconada I, Dordal A, et al. Pharmacological properties of S1RA, a new sigma\u20101 receptor antagonist that inhibits neuropathic pain and activity\u2010induced spinal sensitization. Br J Pharmacol. 2012;166:2289\u2013306.","journal-title":"Br J Pharmacol"},{"key":"834_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/0014-2999(95)00552-8","volume":"294","author":"C-C Chien","year":"1995","unstructured":"Chien C-C, Pasternak G. (\u2013)-Pentazocine analgesia in mice: interactions with a \u03c3 receptor system. Eur J Pharmacol. 1995;294:303\u20138.","journal-title":"Eur J Pharmacol"},{"key":"834_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0304-3940(95)11504-P","volume":"190","author":"C-C Chien","year":"1995","unstructured":"Chien C-C, Pasternak GW. Sigma antagonists potentiate opioid analgesia in rats. Neurosci Lett. 1995;190:137\u20139.","journal-title":"Neurosci Lett"},{"key":"834_CR13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2174\/1871524910909030172","volume":"9","author":"JL Diaz","year":"2009","unstructured":"Diaz JL, Zamanillo D, Corbera J, Baeyens JM, Maldonado R, Peric\u00e0s M\u00c0, et al. Selective sigma-1 (sig1) receptor antagonists: emerging target for the treatment of neuropathic pain. Cent Nerv Syst Agents Med Chem. 2009;9:172\u201383.","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"834_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejphar.2013.04.018","volume":"711","author":"A Vidal-Torres","year":"2013","unstructured":"Vidal-Torres A, de la Puente B, Rocasalbas M, Touri\u00f1o C, Bura SA, Fern\u00e1ndez-Pastor B, et al. Sigma-1 receptor antagonism as opioid adjuvant strategy: enhancement of opioid antinociception without increasing adverse effects. Eur J Pharmacol. 2013;711:63\u201372.","journal-title":"Eur J Pharmacol"},{"key":"834_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s40501-019-00174-y","volume":"6","author":"SH Melton","year":"2019","unstructured":"Melton SH, Melton ST. Current state of the problem: opioid overdose rates and deaths. Curr Treat Options Psychiatry. 2019;6:164\u201377.","journal-title":"Curr Treat Options Psychiatry"},{"key":"834_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1146\/annurev-soc-073117-041351","volume":"45","author":"EM Crimmins","year":"2019","unstructured":"Crimmins EM, Zhang YS. Aging populations, mortality, and life expectancy. Annu Rev Sociol. 2019;45:69\u201389.","journal-title":"Annu Rev Sociol"},{"key":"834_CR17","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.36076\/ppj.2008\/11\/S133","volume":"11","author":"AM Trescot","year":"2008","unstructured":"Trescot AM, Datta S, Lee M, Hansen H. Opioid Pharmacology. Pain Physician. 2008;11:S133\u2013153.","journal-title":"Pain Physician"},{"key":"834_CR18","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0022-3565(25)20242-7","volume":"258","author":"AH Lichtman","year":"1991","unstructured":"Lichtman AH, Martin BR. Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Exp Ther. 1991;258:517\u201323.","journal-title":"J Pharmacol Exp Ther"},{"key":"834_CR19","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0301-0082(00)00031-9","volume":"63","author":"RG Pertwee","year":"2001","unstructured":"Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol. 2001;63:569\u2013611.","journal-title":"Prog Neurobiol"},{"key":"834_CR20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1124\/jpet.116.232421","volume":"357","author":"JN Siemian","year":"2016","unstructured":"Siemian JN, Obeng S, Zhang Y, Zhang Y, Li J-X. Antinociceptive interactions between the Imidazoline I2 receptor agonist 2-BFI and opioids in rats: role of efficacy at the \u00b5-opioid receptor. J Pharmacol Exp Ther. 2016;357:509\u201319.","journal-title":"J Pharmacol Exp Ther"},{"key":"834_CR21","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/S1474-4422(13)70193-5","volume":"12","author":"I Gilron","year":"2013","unstructured":"Gilron I, Jensen TS, Dickenson AH. Combination pharmacotherapy for management of chronic pain: from bench to bedside. Lancet Neurol. 2013;12:1084\u201395.","journal-title":"Lancet Neurol"},{"key":"834_CR22","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1073\/pnas.0409888102","volume":"102","author":"MM Ibrahim","year":"2005","unstructured":"Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci. 2005;102:3093\u20138.","journal-title":"Proc Natl Acad Sci"},{"key":"834_CR23","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1017\/S1461145714000029","volume":"17","author":"P S\u00e1nchez-Bl\u00e1zquez","year":"2014","unstructured":"S\u00e1nchez-Bl\u00e1zquez P, Rodr\u00edguez-Mu\u00f1oz M, Herrero-Labrador R, Burgue\u00f1o J, Zamanillo D, Garz\u00f3n J. The calcium-sensitive sigma-1 receptor prevents cannabinoids from provoking glutamate NMDA receptor hypofunction: implications in antinociception and psychotic diseases. Int J Neuropsychopharmacol. 2014;17:1943\u201355.","journal-title":"Int J Neuropsychopharmacol"},{"key":"834_CR24","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/dta.2156","volume":"9","author":"BA Avery","year":"2017","unstructured":"Avery BA, Vuppala PK, Jamalapuram S, Sharma A, Mesangeau C, Chin FT, et al. Quantification of highly selective sigma-1 receptor antagonist CM304 using liquid chromatography tandem mass spectrometry and its application to a pre\u2010clinical Pharmacokinetic study. Drug Test Anal. 2017;9:1236\u201342.","journal-title":"Drug Test Anal"},{"key":"834_CR25","doi-asserted-by":"publisher","first-page":"8272","DOI":"10.1021\/jm300371c","volume":"55","author":"ML James","year":"2012","unstructured":"James ML, Shen B, Zavaleta CL, Nielsen CH, Mesangeau C, Vuppala PK, et al. New positron emission tomography (PET) radioligand for imaging \u03c3-1 receptors in living subjects. J Med Chem. 2012;55:8272\u201382.","journal-title":"J Med Chem"},{"key":"834_CR26","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1038\/nprot.2006.167","volume":"1","author":"M Solinas","year":"2006","unstructured":"Solinas M, Panlilio LV, Justinova Z, Yasar S, Goldberg SR. Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. Nat Protoc. 2006;1:1194\u2013206.","journal-title":"Nat Protoc"},{"key":"834_CR27","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1007\/s00213-019-05247-7","volume":"236","author":"T Hiranita","year":"2019","unstructured":"Hiranita T, Leon F, Felix JS, Restrepo LF, Reeves ME, Pennington AE, et al. The effects of Mitragynine and morphine on schedule-controlled responding and antinociception in rats. Psychopharmacol. 2019;236:2725\u201334.","journal-title":"Psychopharmacol"},{"key":"834_CR28","doi-asserted-by":"publisher","first-page":"176863","DOI":"10.1016\/j.ejphar.2024.176863","volume":"980","author":"S Obeng","year":"2024","unstructured":"Obeng S, Crowley ML, Mottinelli M, Le\u00f3n F, Zuarth Gonzalez JD, Chen Y, et al. The Mitragyna speciosa (kratom) alkaloid mitragynine: analysis of adrenergic \u03b1(2) receptor activity in vitro and in vivo. Eur J Pharmacol. 2024;980:176863.","journal-title":"Eur J Pharmacol"},{"key":"834_CR29","first-page":"95951","volume":"80","author":"M Metna-Laurent","year":"2017","unstructured":"Metna-Laurent M, Mond\u00e9sir M, Grel A, Vall\u00e9e M, Piazza PV. Cannabinoid\u2010induced tetrad in mice. Curr Protoc Neurosci. 2017;80:95951\u2013595910.","journal-title":"Curr Protoc Neurosci"},{"key":"834_CR30","doi-asserted-by":"publisher","unstructured":"Soto P. Med-PC Data Analysis System 2025. https:\/\/doi.org\/10.17605\/OSF.IO\/7K4TE","DOI":"10.17605\/OSF.IO\/7K4TE"},{"key":"834_CR31","volume-title":"Statistical methods","author":"GW Snedecor","year":"1967","unstructured":"Snedecor GW, Cochran WG. Statistical methods. 6th ed. Ames, Iowa: Iowa State University; 1967.","edition":"6"},{"key":"834_CR32","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0304-3959(02)00041-6","volume":"98","author":"RJ Tallarida","year":"2002","unstructured":"Tallarida RJ. The interaction index: a measure of drug synergism. Pain. 2002;98:163\u20138.","journal-title":"Pain"},{"key":"834_CR33","doi-asserted-by":"publisher","first-page":"173116","DOI":"10.1016\/j.pbb.2021.173116","volume":"202","author":"CF Moore","year":"2021","unstructured":"Moore CF, Davis CM, Harvey EL, Taffe MA, Weerts EM. Appetitive, antinociceptive, and hypothermic effects of vaped and injected \u2206-9-tetrahydrocannabinol (THC) in rats: exposure and dose-effect comparisons by strain and sex. Pharmacol Biochem Behav. 2021;202:173116.","journal-title":"Pharmacol Biochem Behav"},{"key":"834_CR34","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s00213-021-05995-5","volume":"239","author":"CF Moore","year":"2022","unstructured":"Moore CF, Weerts EM. Cannabinoid tetrad effects of oral \u22069-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations. Psychopharmacology. 2022;239:1397\u2013408.","journal-title":"Psychopharmacology"},{"key":"834_CR35","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3389\/fphar.2019.00678","volume":"10","author":"TJ Cirino","year":"2019","unstructured":"Cirino TJ, Eans SO, Medina JM, Wilson LL, Mottinelli M, Intagliata S, et al. Characterization of Sigma 1 receptor antagonist CM-304 and its analog, AZ-66: novel therapeutics against allodynia and induced pain. Front Pharmacol. 2019;10:678.","journal-title":"Front Pharmacol"},{"key":"834_CR36","doi-asserted-by":"publisher","first-page":"103523","DOI":"10.1016\/j.jpet.2025.103523","volume":"392","author":"T Hiranita","year":"2025","unstructured":"Hiranita T, Grisham AK, Mijares AE, Ho NP, France CP. The calcium channel agonist (\u00b1)-BAY-K-8644 attenuates the ability of gabapentinoids to increase the potency of Fentanyl and heroin and decrease the potency of cocaine and d-methamphetamine to elicit discriminative stimulus effects in rats. J Pharmacol Exp Ther. 2025;392:103523.","journal-title":"J Pharmacol Exp Ther"},{"key":"834_CR37","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1111\/j.1476-5381.2012.01942.x","volume":"166","author":"L Romero","year":"2012","unstructured":"Romero L, Zamanillo D, Nadal X, S\u00e1nchez-Arroyos R, Rivera-Arconada I, Dordal A, et al. Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization. Br J Pharmacol. 2012;166:2289\u2013306.","journal-title":"Br J Pharmacol"},{"key":"834_CR38","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/FBP.0000000000000038","volume":"25","author":"G Gris","year":"2014","unstructured":"Gris G, Merlos M, Vela JM, Zamanillo D, Portillo-Salido E. S1RA, a selective sigma-1 receptor antagonist, inhibits inflammatory pain in the Carrageenan and complete freund\u2019s adjuvant models in mice. Behav Pharmacol. 2014;25:226\u201335.","journal-title":"Behav Pharmacol"},{"key":"834_CR39","doi-asserted-by":"publisher","first-page":"37835","DOI":"10.1038\/srep37835","volume":"6","author":"JM Entrena","year":"2016","unstructured":"Entrena JM, S\u00e1nchez-Fern\u00e1ndez C, Nieto FR, Gonz\u00e1lez-Cano R, Yeste S, Cobos EJ, et al. Sigma-1 receptor agonism promotes mechanical allodynia after priming the nociceptive system with capsaicin. Sci Rep. 2016;6:37835.","journal-title":"Sci Rep"},{"key":"834_CR40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejphar.2015.12.012","volume":"771","author":"BA Garc\u00eda-Mart\u00ednez","year":"2016","unstructured":"Garc\u00eda-Mart\u00ednez BA, Jaramillo-Morales OA, Espinosa-Ju\u00e1rez JV, Navarrete-V\u00e1zquez G, Melo-Hern\u00e1ndez LA, Medina-L\u00f3pez JR, et al. Antinociceptive effects of a new sigma-1 receptor antagonist (N-(2-morpholin-4-yl-ethyl)-2-(1-naphthyloxy)acetamide) in two types of nociception. Eur J Pharmacol. 2016;771:10\u20137.","journal-title":"Eur J Pharmacol"},{"key":"834_CR41","doi-asserted-by":"publisher","first-page":"24591","DOI":"10.1038\/srep24591","volume":"6","author":"G Gris","year":"2016","unstructured":"Gris G, Portillo-Salido E, Aubel B, Darbaky Y, Deseure K, Vela JM, et al. The selective sigma-1 receptor antagonist E-52862 attenuates neuropathic pain of different aetiology in rats. Sci Rep. 2016;6:24591.","journal-title":"Sci Rep"},{"key":"834_CR42","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s13311-017-0572-5","volume":"15","author":"J Bruna","year":"2018","unstructured":"Bruna J, Videla S, Argyriou AA, Velasco R, Villoria J, Santos C, et al. Efficacy of a novel sigma-1 receptor antagonist for oxaliplatin-induced neuropathy: a randomized, double-blind, placebo-controlled phase IIa clinical trial. Neurother. 2018;15:178\u201389.","journal-title":"Neurother"},{"key":"834_CR43","doi-asserted-by":"crossref","unstructured":"Wilson LL, Eans SO, Ramadan-Siraj I, Modica MN, Romeo G, Intagliata S, et al. Examination of the novel sigma-1 receptor antagonist, SI 1\/28, for antinociceptive and anti-allodynic efficacy against multiple types of nociception with fewer liabilities of use. Int J Mol Sci. 2022;23.","DOI":"10.3390\/ijms23020615"},{"key":"834_CR44","doi-asserted-by":"crossref","unstructured":"Rossino G, Marra A, Listro R, Peviani M, Poggio E, Curti D, et al. Discovery of RC-752, a novel sigma-1 receptor antagonist with antinociceptive activity: a promising tool for fighting neuropathic pain. Pharmaceuticals (Basel). 2023;16.","DOI":"10.3390\/ph16070962"},{"key":"834_CR45","doi-asserted-by":"publisher","first-page":"114649","DOI":"10.1016\/j.ejmech.2022.114649","volume":"241","author":"T Zhuang","year":"2022","unstructured":"Zhuang T, Xiong J, Ren X, Liang L, Qi Z, Zhang S, et al. Benzylaminofentanyl derivates: discovery of bifunctional \u00b5 opioid and \u03c3(1) receptor ligands as novel analgesics with reduced adverse effects. Eur J Med Chem. 2022;241:114649.","journal-title":"Eur J Med Chem"},{"key":"834_CR46","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3389\/fphar.2019.00422","volume":"10","author":"A Vidal-Torres","year":"2019","unstructured":"Vidal-Torres A, Fern\u00e1ndez-Pastor B, Carceller A, Vela JM, Merlos M, Zamanillo D. Supraspinal and peripheral, but not intrathecal, \u03c3(1)R Blockade by S1RA enhances morphine antinociception. Front Pharmacol. 2019;10:422.","journal-title":"Front Pharmacol"},{"key":"834_CR47","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3389\/fphar.2019.00136","volume":"10","author":"\u00c1 Montilla-Garc\u00eda","year":"2019","unstructured":"Montilla-Garc\u00eda \u00c1, Tejada M, Ruiz-Cantero MC, Bravo-Caparr\u00f3s I, Yeste S, Zamanillo D, et al. Modulation by sigma-1 receptor of morphine analgesia and tolerance: nociceptive pain, tactile allodynia and grip strength deficits during joint inflammation. Front Pharmacol. 2019;10:136.","journal-title":"Front Pharmacol"},{"key":"834_CR48","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.tips.2019.07.006","volume":"40","author":"HR Schmidt","year":"2019","unstructured":"Schmidt HR, Kruse AC. The molecular function of \u03c3 receptors: past, present, and future. Trends Pharmacol Sci. 2019;40:636\u201354.","journal-title":"Trends Pharmacol Sci"},{"key":"834_CR49","doi-asserted-by":"publisher","first-page":"35458","DOI":"10.18632\/oncotarget.6064","volume":"6","author":"M Rodr\u00edguez-Mu\u00f1oz","year":"2015","unstructured":"Rodr\u00edguez-Mu\u00f1oz M, Cort\u00e9s-Montero E, Pozo-Rodrig\u00e1lvarez A, S\u00e1nchez-Bl\u00e1zquez P, Garz\u00f3n-Ni\u00f1o J. The ON:OFF switch, \u03c31R-HINT1 protein, controls GPCR-NMDA receptor cross-regulation: implications in neurological disorders. Oncotarget. 2015;6:35458\u201377.","journal-title":"Oncotarget"},{"key":"834_CR50","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1089\/ars.2014.5993","volume":"22","author":"M Rodr\u00edguez-Mu\u00f1oz","year":"2015","unstructured":"Rodr\u00edguez-Mu\u00f1oz M, S\u00e1nchez-Bl\u00e1zquez P, Herrero-Labrador R, Mart\u00ednez-Murillo R, Merlos M, Vela JM, et al. The \u03c31 receptor engages the redox-regulated HINT1 protein to bring opioid analgesia under NMDA receptor negative control. Antioxid Redox Signal. 2015;22:799\u2013818.","journal-title":"Antioxid Redox Signal"},{"key":"834_CR51","doi-asserted-by":"publisher","first-page":"113658","DOI":"10.1016\/j.ejmech.2021.113658","volume":"223","author":"T Zhuang","year":"2021","unstructured":"Zhuang T, Xiong J, Hao S, Du W, Liu Z, Liu B, et al. Bifunctional \u00b5 opioid and \u03c3(1) receptor ligands as novel analgesics with reduced side effects. Eur J Med Chem. 2021;223:113658.","journal-title":"Eur J Med Chem"},{"key":"834_CR52","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1111\/bph.13024","volume":"172","author":"MA Taffe","year":"2015","unstructured":"Taffe MA, Creehan KM, Vandewater SA. Cannabidiol fails to reverse hypothermia or locomotor suppression induced by \u22069-tetrahydrocannabinol in S prague\u2010D Awley rats. Br J Pharmacol. 2015;172:1783\u201391.","journal-title":"Br J Pharmacol"},{"key":"834_CR53","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1124\/jpet.301.3.963","volume":"301","author":"SM Rawls","year":"2002","unstructured":"Rawls SM, Cabassa J, Geller EB, Adler MW. CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl) -6H-pyrrolo[3,2,1 ij]quinolin-6-one]-induced hypothermia. J Pharmacol Exp Ther. 2002;301:963\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"834_CR54","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.phrs.2015.09.006","volume":"102","author":"S Tai","year":"2015","unstructured":"Tai S, Hyatt W, Gu C, Franks LN, Vasiljevik T, Brents LK, et al. Repeated administration of phytocannabinoid \u22069-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner. Pharmacol Res. 2015;102:22\u201332.","journal-title":"Pharmacol Res"},{"key":"834_CR55","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejphar.2012.07.029","volume":"691","author":"MJ Seminerio","year":"2012","unstructured":"Seminerio MJ, Robson MJ, McCurdy CR, Matsumoto RR. Sigma receptor antagonists attenuate acute methamphetamine-induced hyperthermia by a mechanism independent of IL-1\u03b2 mRNA expression in the hypothalamus. Eur J Pharmacol. 2012;691:103\u20139.","journal-title":"Eur J Pharmacol"},{"key":"834_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0165-0173(01)00054-6","volume":"36","author":"C Davidson","year":"2001","unstructured":"Davidson C, Gow AJ, Lee TH, Ellinwood EH. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev. 2001;36:1\u201322.","journal-title":"Brain Res Brain Res Rev"},{"key":"834_CR57","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0022-3565(25)38650-7","volume":"268","author":"JF Bowyer","year":"1994","unstructured":"Bowyer JF, Davies DL, Schmued L, Broening HW, Newport GD, Slikker W Jr., et al. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther. 1994;268:1571\u201380.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00834-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00834-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00834-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T04:43:15Z","timestamp":1773204195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-026-00834-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["834"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00834-w","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Behavioral protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Florida, which was fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC), and were written in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate declarations"}},{"value":"CRM is a founding scientific advisor to PainVox which holds the intellectual property rights to CM304. The remaining authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}